Prostate cancer (PCa) progression is driven by complex molecular reprogramming, yet distinguishing indolent from aggressive disease remains a challenge. We performed an integrative transcriptomic analysis of 1232 PCa samples spanning normal prostate ...
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Nov 3, 2025
This study aimed to explore the prognostic value of the artificial intelligence-assisted lesion tracking applied to prostate-specific membrane antigen (PSMA) PET in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with PS...
International journal of pharmaceutics
Aug 24, 2025
PURPOSE: The development of a novel lipid-based formulation for apalutamide, a potent androgen receptor inhibitor for non-metastatic castration-resistant prostate cancer (nmCRPC), is explored in this study.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Aug 2, 2025
Despite therapeutic advancements, metastatic and nonmetastatic castration-resistant prostate cancer (mCRPC and nmCRPC) remain incurable due to drug resistance, partly due to Androgen receptor (AR) gene abnormalities and splice variants. An Augmented ...
International journal of surgery (London, England)
May 1, 2025
BACKGROUND: Nonmetastatic castration-resistant prostate cancer (nmCRPC) is a clinical challenge due to the high progression rate to metastasis and mortality. To date, no prognostic model has been developed to predict the metastatic probability for nm...
The objective of this study was to employ machine learning to identify shared differentially expressed genes (DEGs) in prostate cancer (PCa) initiation and castration resistance, aiming to establish a robust prognostic model and enhance understanding...
PURPOSE: The SPARTAN trial demonstrated that the addition of apalutamide to androgen deprivation therapy improves outcomes among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). We applied a previously reported digital histo...
BACKGROUND AND OBJECTIVE: Owing to the expansion of treatment options for metastatic hormone-sensitive prostate cancer (mHSPC) and an appreciation of clinical subgroups with differential prognosis and treatment responses, prognostic and predictive bi...
BACKGROUND: Prostate cancer is the second leading cause of death among American men. If detected and treated at an early stage, prostate cancer is often curable. However, an advanced stage such as metastatic castration-resistant prostate cancer (mCRP...
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Nov 6, 2024
BACKGROUND: There is a need for clinically actionable prognostic and predictive tools to guide the management of oligometastatic castration-sensitive prostate cancer (omCSPC).
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.